Genomics, transcriptional profiling, and heart failure

Area of Science:

• Genomics and molecular biology
• Cardiovascular research
• Precision medicine

Background:

• Technological advancements in deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) profiling have deepened the understanding of complex diseases like heart failure (HF).
• Identification of genetic mutations in hereditary cardiomyopathies offers pathophysiological insights and diagnostic tools for rare conditions.
• Genome-wide association studies and clinical trial genotyping reveal common disease- and treatment-modifying genes, explaining patient variability in HF.

Purpose of the Study:

• To explore how genetic and gene expression profiling can improve the diagnosis and treatment of heart failure (HF) and cardiomyopathies.
• To highlight the role of advanced molecular techniques in understanding the interplay between genes, environment, and tissues in HF.
• To discuss the potential of personalized medicine approaches in managing the HF epidemic.

Main Methods:

• Genotyping of clinical trial participants.
• Genome-wide association studies (GWAS).
• Gene expression profiling in diseased tissues and circulating cells from animal models and patients.
• Analysis of DNA and mRNA for identifying disease-related genetic variations and expression patterns.

Main Results:

• Genetic profiling has identified mutations responsible for hereditary cardiomyopathies, aiding diagnosis and understanding pathophysiology.
• GWAS and genotyping have accelerated the discovery of genes influencing HF development and treatment response.
• Gene expression studies in HF provide novel insights into disease mechanisms, identifying potential diagnostic and therapeutic targets.
• Genetic and expression profiling demonstrate potential to enhance diagnostic accuracy and guide therapeutic selection for cardiomyopathies and HF.

Conclusions:

• Genetic and gene expression profiling are crucial for advancing the understanding and management of heart failure (HF) and cardiomyopathies.
• These molecular profiling techniques offer a rational basis for personalized therapeutic strategies, improving patient outcomes.
• Integration of complex genomic data with clinical information technology will enable tailored prevention and treatment for the growing HF epidemic.